Clinical Trial Detail

NCT ID NCT03307759
Title Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma (SABRseq)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Peter MacCallum Cancer Centre, Australia
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.